Metastatic castration-resistant prostate cancer (mCRPC) is a severe form of late-stage disease where the tumor can no longer ...

The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically ...

Neal Shore, MD, FACS, discussed a study on survival outcomes in metastatic castration-sensitive prostate cancer comparing ...

Men who undergo prostate cancer treatment face a greatly increased risk of life-altering, long-term complications, a new study finds.

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

Prostate cancer patients may have long-term complications from treatment ... Nov. 7 (UPI) -- The U.S. Food and Drug ...

A new, peer-reviewed study by researchers at Stanford University identified 22 pesticides "consistently associated with the incidence of prostate cancer in the United States." Here's what to know.

There have been clinical trials with different immunotherapy approaches with cancer, so experts believe there could be immune-targeting drugs for prostate cancer within the next five years.

Essa Pharma is exploring “strategic options” as it ends work on its prostate cancer drug that failed a mid-stage test. The company's shares {$EPIX} nosedived by as much as 65 ...